Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Gary Grover
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Disorders
Chemicals & Drugs
Physiology
Anatomy
Procedures
Sign-in to see full Profile
Network (preview)
65
Sleph, Paul
14
Atwal, Karnail
14
D'Alonzo, Albert
13
Darbenzio, Raymond
12
Normandin, Diane
11
Seethala, Ramakrishna
7
Malm, Johan
7
Golla, Rajasree
6
McCullough, John
6
Robl, Jeffrey
5
Ostrowski, Jacek
5
Slusarchyk, Dorothy
5
Ogletree, Martin
5
Beehler, Blake
4
Baxter, John
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Gary Grover (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Nirschl Alexandra A; Zou Yan; Krystek Stanley R; Sutton James C; Simpkins Ligaya M; Lupisella John A; Kuhns Joyce E; Seethala Ramakrishna; Golla Rajasree; Sleph Paul G; Beehler Blake C; Grover Gary J; Egan Donald; Fura Aberra; Vyas Viral P; Li Yi-Xin; Sack John S; Kish Kevin F; An Yongmi; Bryson James A; Gougoutas Jack Z; DiMarco John; Zahler Robert; Ostrowski Jacek; Hamann Lawrence G
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.
Journal of medicinal chemistry 2009;52(9):2794-8.
-
2008: Bryzgalova Galina; Effendic Suad; Khan Akhtar; Rehnmark Stefan; Barbounis Peter; Boulet Jamie; Dong Gao; Singh Rajni; Shapses Sue; Malm Johan; Webb Paul; Baxter John D; Grover Gary J
Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
The Journal of steroid biochemistry and molecular biology 2008;111(3-5):262-7.
-
2008: Li James J; Wang Haixia; Li Jun; Qu Fucheng; Swartz Stephen G; Hernández Andrés S; Biller Scott A; Robl Jeffrey A; Tino Joseph A; Slusarchyk Dorothy; Seethala Ramakrishna; Sleph Paul; Yan Mujing; Grover Gary; Flynn Neil; Murphy Brian J; Gordon David
Tetrazole based amides as growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2008;18(8):2536-9.
-
2008: Li Jun; Chen Stephanie Y; Tao Shiwei; Wang Haixia; Li James J; Swartz Steve; Musial Christa; Hernandez Andres A; Flynn Neil; Murphy Brian J; Beehler Blake; Dickinson Kenneth E; Giupponi Leah; Grover Gary; Seethala Ramakrishna; Sleph Paul; Slusarchyk Dorothy; Yan Mujing; Humphreys William G; Zhang Hongjian; Ewing William R; Robl Jeffrey A; Gordon David; Tino Joseph A
Design and synthesis of tetrazole-based growth hormone secretagogue: the SAR studies of the O-benzyl serine side chain.
Bioorganic & medicinal chemistry letters 2008;18(6):1825-9.
-
2008: Hernández Andrés S; Swartz Stephen G; Slusarchyk Dorothy; Yan Mujing; Seethala R Krishna; Sleph Paul; Grover Gary; Dickinson Kenneth; Giupponi Leah; Harper Timothy W; Humphreys W Griffith; Longhi Daniel A; Flynn Neil; Murphy Brian J; Gordon David A; Biller Scott A; Robl Jeffrey A; Tino Joseph A
Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2008;18(6):2067-72.
-
2007: Hernández Andrés S; Cheng Peter T W; Musial Christa M; Swartz Stephen G; George Rocco J; Grover Gary; Slusarchyk Dorothy; Seethala R Krishna; Smith Mark; Dickinson Kenneth; Giupponi Leah; Longhi Daniel A; Flynn Neil; Murphy Brian J; Gordon David A; Biller Scott A; Robl Jeffrey A; Tino Joseph A
Discovery, synthesis, and structure-activity studies of tetrazole based growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2007;17(21):5928-33.
-
2007: Manfredi Mark C; Bi Yingzhi; Nirschl Alexandra A; Sutton James C; Seethala Ramakrishna; Golla Rajasree; Beehler Blake C; Sleph Paul G; Grover Gary J; Ostrowski Jacek; Hamann Lawrence G
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
Bioorganic & medicinal chemistry letters 2007;17(16):4487-90.
-
2007: Garg Neeraj; Li Yi-Lin; Garcia Collazo Ana Maria; Litten Chris; Ryono Denis E; Zhang Minsheng; Caringal Yolanda; Brigance Robert P; Meng Wei; Washburn William N; Agback Peter; Mellström Karin; Rehnmark Stefan; Rahimi-Ghadim Mahmoud; Norin Thomas; Grynfarb Marlena; Sandberg Johnny; Grover Gary; Malm Johan
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
Bioorganic & medicinal chemistry letters 2007;17(15):4131-4.
-
2007: Grover Gary J; Dunn Celeste; Nguyen Ngoc-Ha; Boulet Jamie; Dong Gao; Domogauer Jason; Barbounis Peter; Scanlan Thomas S
Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats.
The Journal of pharmacology and experimental therapeutics 2007;322(1):385-90.
-
2007: Li James J; Sutton James C; Nirschl Alexandra; Zou Yan; Wang Haixia; Sun Chongqing; Pi Zulan; Johnson Rebecca; Krystek Stanley R; Seethala Ramakrishna; Golla Rajasree; Sleph Paul G; Beehler Blake C; Grover Gary J; Fura Aberra; Vyas Viral P; Li Cindy Y; Gougoutas Jack Z; Galella Michael A; Zahler Robert; Ostrowski Jacek; Hamann Lawrence G
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
Journal of medicinal chemistry 2007;50(13):3015-25.
-
2007: Grover Gary J; Mellström Karin; Malm Johan
Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes.
Current vascular pharmacology 2007;5(2):141-54.
-
2007: Devasthale Pratik V; Chen Sean; Jeon Yoon; Qu Fucheng; Ryono Denis E; Wang Wei; Zhang Hao; Cheng Lin; Farrelly Dennis; Golla Rajasree; Grover Gary; Ma Zhengping; Moore Lisa; Seethala Ramakrishna; Sun Wei; Doweyko Arthur M; Chandrasena Gamini; Sleph Paul; Hariharan Narayanan; Cheng Peter T W
Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
Bioorganic & medicinal chemistry letters 2007;17(8):2312-6.
-
2007: Malm J; Grover G J; Färnegårdh M
Recent advances in the development of agonists selective for beta1-type thyroid hormone receptor.
Mini reviews in medicinal chemistry 2007;7(1):79-86.
-
2007: Ostrowski Jacek; Kuhns Joyce E; Lupisella John A; Manfredi Mark C; Beehler Blake C; Krystek Stanley R; Bi Yingzhi; Sun Chongqing; Seethala Ramakrishna; Golla Rajasree; Sleph Paul G; Fura Aberra; An Yongmi; Kish Kevin F; Sack John S; Mookhtiar Kasim A; Grover Gary J; Hamann Lawrence G
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.
Endocrinology 2007;148(1):4-12.
-
2006: Sun Chongqing; Robl Jeffrey A; Wang Tammy C; Huang Yanting; Kuhns Joyce E; Lupisella John A; Beehler Blake C; Golla Rajasree; Sleph Paul G; Seethala Ramakrishna; Fura Aberra; Krystek Stanley R; An Yongmi; Malley Mary F; Sack John S; Salvati Mark E; Grover Gary J; Ostrowski Jacek; Hamann Lawrence G
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
Journal of medicinal chemistry 2006;49(26):7596-9.
-
2006: Koehler Konrad; Gordon Sandra; Brandt Peter; Carlsson Bo; Bäcksbro-Saeidi Anna; Apelqvist Theresa; Agback Peter; Grover Gary J; Nelson William; Grynfarb Marlena; Färnegårdh Mathias; Rehnmark Stefan; Malm Johan
Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor.
Journal of medicinal chemistry 2006;49(23):6635-7.
-
2006: Beehler Blake C; Sleph Paul G; Benmassaoud Latifa; Grover Gary J
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Experimental biology and medicine (Maywood, N.J.) 2006;231(3):335-41.
-
2005: Li James J; Wang Haixia; Qu Fucheng; Musial Christa; Tino Joseph A; Robl Jeffrey A; Slusarchyk Dorothy; Golla Rajasree; Seethala Ramakrishna; Dickinson Kenneth; Giupponi Leah; Grover Gary; Sleph Paul; Flynn Neil; Murphy Brian J; Gordon David; Kung Melissa; Stoffel Robert
Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues.
Bioorganic & medicinal chemistry letters 2005;15(7):1799-802.
-
2004: Grover Gary J; Atwal Karnail S; Sleph Paul G; Wang Feng-Li; Monshizadegan Hossain; Monticello Thomas; Green David W
Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.
American journal of physiology. Heart and circulatory physiology 2004;287(4):H1747-55.
-
2004: Grover Gary J; Egan Donald M; Sleph Paul G; Beehler Blake C; Chiellini Grazia; Nguyen Ngoc-Ha; Baxter John D; Scanlan Thomas S
Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine.
Endocrinology 2004;145(4):1656-61.
-
2004: Atwal Karnail S; Wang Paulina; Rogers W Lynn; Sleph Paul; Monshizadegan Hossain; Ferrara Francis N; Traeger Sarah; Green David W; Grover Gary J
Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.
Journal of medicinal chemistry 2004;47(5):1081-4.
-
2003: Grover Gary J; Burkett Dennis E; Parham Charles S; Scalese Robert J; Sadanaga Kenneth K
Protective effect of mitochondrial KATP activation in an isolated gracilis model of ischemia and reperfusion in dogs.
Journal of cardiovascular pharmacology 2003;42(6):790-2.
-
2003: Oldenburg Olaf; Yang Xi-Ming; Krieg Thomas; Garlid Keith D; Cohen Michael V; Grover Gary J; Downey James M
P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts.
Journal of molecular and cellular cardiology 2003;35(9):1035-42.
-
2003: Grover Gary J; Mellström Karin; Ye Liu; Malm Johan; Li Yi-Lin; Bladh Lars-Göran; Sleph Paul G; Smith Mark A; George Rocco; Vennström Björn; Mookhtiar Kasim; Horvath Ryan; Speelman Jessica; Egan Donald; Baxter John D
Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(17):10067-72.
-
2003: Gross Eric R; Peart Jason N; Hsu Anna K; Grover Gary J; Gross Garrett J
K(ATP) opener-induced delayed cardioprotection: involvement of sarcolemmal and mitochondrial K(ATP) channels, free radicals and MEK1/2.
Journal of molecular and cellular cardiology 2003;35(8):985-92.
-
2003: Ye Liu; Li Yi-Lin; Mellström Karin; Mellin Charlotta; Bladh Lars-Göran; Koehler Konrad; Garg Neeraj; Garcia Collazo Ana Maria; Litten Chris; Husman Bolette; Persson Karina; Ljunggren Jan; Grover Gary; Sleph Paul G; George Rocco; Malm Johan
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
Journal of medicinal chemistry 2003;46(9):1580-8.
-
2002: Grover Gary J; D'Alonzo Albert J; Darbenzio Raymond B; Parham Charles S; Hess Thomas A; Bathala Mohinder S
In vivo characterization of the mitochondrial selective K(ATP) opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride (BMS-191095): cardioprotective, hemodynamic, and electrophysiological effects.
The Journal of pharmacology and experimental therapeutics 2002;303(1):132-40.
-
2002: Grover Gary J; Atwal Karnail S
Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia.
Cardiovascular drug reviews 2002;20(2):121-36.
-
2001: Grover G J; D'Alonzo A J; Garlid K D; Bajgar R; Lodge N J; Sleph P G; Darbenzio R B; Hess T A; Smith M A; Paucek P; Atwal K S
Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
The Journal of pharmacology and experimental therapeutics 2001;297(3):1184-92.
-
2000: Trost S U; Swanson E; Gloss B; Wang-Iverson D B; Zhang H; Volodarsky T; Grover G J; Baxter J D; Chiellini G; Scanlan T S; Dillmann W H
The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.
Endocrinology 2000;141(9):3057-64.
-
2000: Grover G J; Garlid K D
ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology.
Journal of molecular and cellular cardiology 2000;32(4):677-95.
-
1999: Ding C Z; Rovnyak G C; Misra R N; Grover G J; Miller A V; Ahmed S Z; Kelly Y; Normandin D E; Sleph P G; Atwal K S
Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
Journal of medicinal chemistry 1999;42(18):3711-7.
-
1998: D'Alonzo A J; Zhu J L; Darbenzio R B; Dorso C R; Grover G J
Proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea-pig hearts.
Journal of molecular and cellular cardiology 1998;30(2):415-23.
-
1998: Atwal K S; Grover G J; Lodge N J; Normandin D E; Traeger S C; Sleph P G; Cohen R B; Bryson C C; Dickinson K E
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
Journal of medicinal chemistry 1998;41(3):271-5.
-
1998: Green D W; Murray H N; Sleph P G; Wang F L; Baird A J; Rogers W L; Grover G J
Preconditioning in rat hearts is independent of mitochondrial F1F0 ATPase inhibition.
The American journal of physiology 1998;274(1 Pt 2):H90-7.
-
1997: Garlid K D; Paucek P; Yarov-Yarovoy V; Murray H N; Darbenzio R B; D'Alonzo A J; Lodge N J; Smith M A; Grover G J
Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection.
Circulation research 1997;81(6):1072-82.
-
1997: Grover G J
Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion.
Canadian journal of physiology and pharmacology 1997;75(4):309-15.
-
1997: Gomoll A W; Roth R A; Swillo R E; Baird A J; Sargent C S; Behling R W; Malone H J; Grover G J
Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.
The Journal of pharmacology and experimental therapeutics 1997;281(1):24-33.
-
1997: Gross G J; Mei D A; Sleph P G; Grover G J
Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.
The Journal of pharmacology and experimental therapeutics 1997;280(2):533-40.
-
1997: Rovnyak G C; Ahmed S Z; Ding C Z; Dzwonczyk S; Ferrara F N; Humphreys W G; Grover G J; Santafianos D; Atwal K S; Baird A J; McLaughlin L G; Normandin D E; Sleph P G; Traeger S C
Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.
Journal of medicinal chemistry 1997;40(1):24-34.
-
1997: Grover G J; Sleph P G; Dzwonczyk S; Malone H J; Behling R W
Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations.
Journal of cardiovascular pharmacology 1997;29(1):28-38.
-
1996: Grover G J; D'Alonzo A J; Dzwonczyk S; Parham C S; Darbenzio R B
Preconditioning is not abolished by the delayed rectifier K+ blocker dofetilide.
The American journal of physiology 1996;271(3 Pt 2):H1207-14.
-
1996: Vesterqvist O; Sargent C A; Grover G J; Ogletree M L
Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit hearts.
Cardiovascular research 1996;31(6):932-40.
-
1996: Grover G J; Baird A J; Sleph P G
Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
Cardiovascular research 1996;31(4):511-7.
-
1996: D'Alonzo A J; Grover G J; Darbenzio R B; Sewter J C; Hess T A; Dzwonczyk S; Sleph P G
Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
Pharmacology 1996;52(2):101-12.
-
1996: Sargent C A; Wilde M W; Dzwonczyk S; Tuttle J G; Murray H N; Atwal K; Grover G J
Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts.
Cardiovascular research 1996;31(2):270-7.
-
1996: Grover G J; Parham C S; Whigan D B; Mitroka J G
BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs.
The Journal of pharmacology and experimental therapeutics 1996;276(2):380-7.
-
1996: Grover G J; Dzwonczyk S; Monticello T M
Comparative cardioprotective effects of cromakalim and diltiazem in ischemic hypertrophied rat hearts.
The American journal of physiology 1996;270(1 Pt 2):H174-82.
-
1996: Atwal K S; Ferrara F N; Ding C Z; Grover G J; Sleph P G; Dzwonczyk S; Baird A J; Normandin D E
Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: replacement of the benzopyran portion.
Journal of medicinal chemistry 1996;39(1):304-13.
-
1996: Grover G J
The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future.
EXS 1996;76():313-24.
-
1995: D'Alonzo A J; Darbenzio R B; Sewter J C; Hess T A; Grover G J; Sleph P G; Normandin D E; Lodge N J
A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog.
European journal of pharmacology 1995;294(1):271-80.
-
1995: Grover G J; Sleph P G
Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution.
Journal of cardiovascular pharmacology 1995;26(5):698-706.
-
1995: Grover G J; D'Alonzo A J; Hess T; Sleph P G; Darbenzio R B
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Cardiovascular research 1995;30(5):731-8.
-
1995: Atwal K S; Grover G J; Ahmed S Z; Sleph P G; Dzwonczyk S; Baird A J; Normandin D E
Cardioselective anti-ischemic ATP-sensitive potassium channel openers. 3. Structure-activity studies on benzopyranyl cyanoguanidines: modification of the cyanoguanidine portion.
Journal of medicinal chemistry 1995;38(17):3236-45.
-
1995: Grover G J; Dzwonczyk S; McMullen D M; Normandin D E; Parham C S; Sleph P G; Moreland S
Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946].
Journal of cardiovascular pharmacology 1995;26(2):289-94.
-
1995: Grover G J; D'Alonzo A J; Parham C S; Darbenzio R B
Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
Journal of cardiovascular pharmacology 1995;26(1):145-52.
-
1995: Atwal K S; Grover G J; Ferrara F N; Ahmed S Z; Sleph P G; Dzwonczyk S; Normandin D E
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.
Journal of medicinal chemistry 1995;38(11):1966-73.
-
1995: Grover G J; Parham C S; Youssef S; Ogletree M L
Protective effect of the serotonin receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischemia.
Pharmacology 1995;50(5):286-97.
-
1995: Grover G J; Murray H N; Baird A J; Dzwonczyk S
The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts.
European journal of pharmacology 1995;277(2-3):271-4.
-
1995: Weselcouch E O; Baird A J; Sleph P G; Dzwonczyk S; Murray H N; Grover G J
Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heart.
Cardiovascular research 1995;29(1):126-32.
-
1995: Grover G J; McCullough J R; D'Alonzo A J; Sargent C A; Atwal K S
Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Journal of cardiovascular pharmacology 1995;25(1):40-50.
-
1995: D'Alonzo A J; Grover G J; Darbenzio R B; Hess T A; Sleph P G; Dzwonczyk S; Zhu J L; Sewter J C
In vitro effects of capsaicin: antiarrhythmic and antiischemic activity.
European journal of pharmacology 1995;272(2-3):269-78.
-
1995: Weselcouch E O; Baird A J; Sleph P; Grover G J
Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts.
The American journal of physiology 1995;268(1 Pt 2):H242-9.
-
1994: Gomoll A W; Grover G J; Ogletree M L
Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.
Journal of cardiovascular pharmacology 1994;24(6):960-8.
-
1994: Sargent C A; Dzwonczyk S; Sleph P; Wilde M; Grover G J
Pyruvate increases threshold for preconditioning in globally ischemic rat hearts.
The American journal of physiology 1994;267(4 Pt 2):H1403-9.
-
1994: Grover G J; Schumacher W A; Ogletree M L
Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.
Journal of cardiovascular pharmacology 1994;24(3):493-9.
-
1994: Sargent C A; Dzwonczyk S; Grover G J
The effect of alpha 2-adrenoceptor antagonists in isolated globally ischemic rat hearts.
European journal of pharmacology 1994;261(1-2):25-32.
-
1994: D'Alonzo A J; Darbenzio R B; Hess T A; Sewter J C; Sleph P G; Grover G J
Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.
Cardiovascular research 1994;28(6):881-7.
-
1994: Grover G J
Protective effects of ATP sensitive potassium channel openers in models of myocardial ischaemia.
Cardiovascular research 1994;28(6):778-82.
-
1994: Grover G J; D'Alonzo A J; Sleph P G; Dzwonczyk S; Hess T A; Darbenzio R B
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
The Journal of pharmacology and experimental therapeutics 1994;269(2):536-40.
-
1994: Vesterqvist O; Sargent C A; Grover G J; Warrack B M; DiDonato G C; Ogletree M L
Characterization of rabbit myocardial phospholipase A2 activity using endogenous phospholipid substrates.
Analytical biochemistry 1994;217(2):210-9.
-
1994: Grover G J; Sleph P G
The cardioprotective effects of R 75231 and lidoflazine are not caused by adenosine A1 receptor activation.
The Journal of pharmacology and experimental therapeutics 1994;268(1):90-6.
-
1994: Grover G J
Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Journal of cardiovascular pharmacology 1994;24 Suppl 4():S18-27.
-
1993: Atwal K S; Grover G J; Ahmed S Z; Ferrara F N; Harper T W; Kim K S; Sleph P G; Dzwonczyk S; Russell A D; Moreland S
Cardioselective anti-ischemic ATP-sensitive potassium channel openers.
Journal of medicinal chemistry 1993;36(24):3971-4.
-
1993: Grover G J; Sleph P G; Dzwonczyk S; McCullough J R
Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
The Journal of pharmacology and experimental therapeutics 1993;267(1):102-7.
-
1993: Grover G J; Sargent C A; Dzwonczyk S; Normandin D E; Antonaccio M J
Protective effect of serotonin (5-HT2) receptor antagonists in ischemic rat hearts.
Journal of cardiovascular pharmacology 1993;22(4):664-72.
-
1993: Sargent C A; Sleph P G; Dzwonczyk S; Normandin D; Antonaccio M J; Grover G J
Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075.
Journal of cardiovascular pharmacology 1993;22(4):564-70.
-
1993: Sargent C A; Grover G J; Antonaccio M J; McCullough J R
The cardioprotective, vasorelaxant and electrophysiological profile of the large conductance calcium-activated potassium channel opener NS-004.
The Journal of pharmacology and experimental therapeutics 1993;266(3):1422-9.
-
1993: Grover G J; Dzwonczyk S; Parham C S
The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion.
Cardiovascular research 1993;27(9):1613-8.
-
1993: Grover G J
An explanation for the reported observation that ATP dependent potassium channel openers fail to mimic preconditioning.
Cardiovascular research 1993;27(9):1564.
-
1993: Sargent C A; Vesterqvist O; Ogletree M L; Grover G J
Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat hearts.
Journal of molecular and cellular cardiology 1993;25(8):905-13.
-
1993: Sargent C A; Sleph P G; Dzwonczyk S; Smith M A; Normandin D; Antonaccio M J; Grover G J
Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.
The Journal of pharmacology and experimental therapeutics 1993;265(2):609-18.
-
1993: Grover G J; Dzwonczyk S; Sleph P G; Sargent C A
The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.
The Journal of pharmacology and experimental therapeutics 1993;265(2):559-64.
-
1992: Grover G J; Sleph P G; Fox M; Trippodo N C
Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts.
The Journal of pharmacology and experimental therapeutics 1992;263(3):1074-82.
-
1992: D'Alonzo A J; Darbenzio R B; Parham C S; Grover G J
Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration.
Cardiovascular research 1992;26(11):1046-53.
-
1992: Grover G J; Sleph P G; Dzwonczyk S
Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors.
Circulation 1992;86(4):1310-6.
-
1992: Sargent C A; Vesterqvist O; McCullough J R; Ogletree M L; Grover G J
Effect of the phospholipase A2 inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts.
The Journal of pharmacology and experimental therapeutics 1992;262(3):1161-7.
-
1992: Sargent C A; Sleph P G; Dzwonczyk S; Smith M A; Grover G J
Effect of calmodulin and protein kinase C inhibitors on globally ischemic rat hearts.
Journal of cardiovascular pharmacology 1992;20(2):251-60.
-
1992: Vesterqvist O; Sargent C A; Taylor S C; Newburger J; Tymiak A A; Grover G J; Ogletree M L
Quantitation of lysophosphatidylcholine molecular species in rat cardiac tissue.
Analytical biochemistry 1992;204(1):72-8.
-
1992: Clayton F C; Hess T A; Smith M A; Grover G J
Coronary reactive hyperemia and adenosine-induced vasodilation are mediated partially by a glyburide-sensitive mechanism.
Pharmacology 1992;44(2):92-100.
-
1992: Sargent C A; Dzwonczyk S; Grover G J
Effect of the potassium channel opener EMD 56431 on globally ischemic rat hearts.
Pharmacology 1992;45(5):260-8.
-
1991: McCullough J R; Normandin D E; Conder M L; Sleph P G; Dzwonczyk S; Grover G J
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
Circulation research 1991;69(4):949-58.
-
1991: Sargent C A; Smith M A; Dzwonczyk S; Sleph P G; Grover G J
Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
The Journal of pharmacology and experimental therapeutics 1991;259(1):97-103.
-
1991: Grover G J; Sleph P G; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman D W
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
The Journal of pharmacology and experimental therapeutics 1991;257(3):919-29.
-
1991: Grover G J; Newburger J; Sleph P G; Dzwonczyk S; Taylor S C; Ahmed S Z; Atwal K S
Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.
The Journal of pharmacology and experimental therapeutics 1991;257(1):156-62.
-
1991: Grover G J; Parham C S; Schumacher W A
The cardioprotective effects of the thromboxane receptor antagonist SQ 30,741 are not reversed by aspirin.
Basic research in cardiology 1991;86(2):99-106.
-
1991: Grover G J; Parham C S; Schumacher W A
The combined antiischemic effects of the thromboxane receptor antagonist SQ 30,741 and tissue-type plasminogen activator.
American heart journal 1991;121(2 Pt 1):426-33.
-
1990: Grover G J; Sleph P G; Dzwonczyk S
Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
Journal of cardiovascular pharmacology 1990;16(6):853-64.
-
1990: Grover G J; Dzwonczyk S; Sleph P G
Reduction of ischemic damage in isolated rat hearts by the potassium channel opener, RP 52891.
European journal of pharmacology 1990;191(1):11-8.
-
1990: Grover G J; Dzwonczyk S; Sleph P G
Ruthenium red improves postischemic contractile function in isolated rat hearts.
Journal of cardiovascular pharmacology 1990;16(5):783-9.
-
1990: Moreland S; Antes L M; McMullen D M; Sleph P G; Grover G J
Myosin light-chain phosphorylation and vascular resistance in canine anterior tibial arteries in situ.
Pflügers Archiv : European journal of physiology 1990;417(2):180-4.
-
1990: Grover G J; Sleph P G; Parham C S; Brittain R J; Krapcho J; Moreland S
Anti-ischemic activity of the novel benzazepine calcium antagonist SQ 31,486.
Journal of cardiovascular pharmacology 1990;16(2):219-27.
-
1990: Grover G J; Sleph P G; Weiss H R
Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog.
The Journal of pharmacology and experimental therapeutics 1990;253(3):1097-102.
-
1990: Grover G J; Sleph P G; Parham C S
Nicorandil improves postischemic contractile function independently of direct myocardial effects.
Journal of cardiovascular pharmacology 1990;15(5):698-705.
-
1990: Grover G J; Dzwonczyk S; Parham C S; Sleph P G
The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1990;4(2):465-74.
-
1990: Schumacher W A; Grover G J
The thromboxane receptor antagonist SQ 30,741 reduces myocardial infarct size in monkeys when given during reperfusion at a threshold dose for improving reflow during thrombolysis.
Journal of the American College of Cardiology 1990;15(4):883-9.
-
1990: Grover G J; Dzwonczyk S; Sleph P G
Comparative anti-ischemic effects of dihydropyridine calcium antagonists in isolated perfused rat hearts: relationship of cardiodepression and cardioprotection.
Pharmacology 1990;40(3):137-49.
-
1990: Grover G J; Hedberg A; Ogletree M L
Direct myocardial effects of the thromboxane A2/prostaglandin H2 agonists U-46619 and SQ 26,655 under ischemic and nonischemic conditions.
Pharmacology 1990;41(1):1-15.
-
1989: Grover G J; Parham C S; Sleph P G; Moreland S
Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765.
The Journal of pharmacology and experimental therapeutics 1989;251(3):1020-5.
-
1989: Grover G J
Thromboxane receptor blockade with SQ 30,741 improves post-ischemic myocardial function in anesthetized dogs.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1989;192(1):56-60.
-
1989: Grover G J; McCullough J R; Henry D E; Conder M L; Sleph P G
Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
The Journal of pharmacology and experimental therapeutics 1989;251(1):98-104.
-
1989: Grover G J; Sleph P G
Dissociation of cardiodepression from cardioprotection with calcium antagonists: diltiazem protects ischemic rat myocardium with a lower functional cost as compared with verapamil or nifedipine.
Journal of cardiovascular pharmacology 1989;14(2):331-40.
-
1989: Grover G J; Parham C S
Role of thromboxane A2 in the control of myocardial O2 supply/consumption balance and severity of ischemia during pacing-induced ischemia.
Circulation research 1989;64(3):575-82.
-
1989: Grover G J; Schumacher W A
Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
The Journal of pharmacology and experimental therapeutics 1989;248(2):484-91.
-
1989: Grover G J; Schumacher W A
The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia.
Basic research in cardiology 1989;84(1):103-10.
-
1989: Cushman D W; Wang F L; Fung W C; Grover G J; Harvey C M; Scalese R J; Mitch S L; DeForrest J M
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
British journal of clinical pharmacology 1989;28 Suppl 2():115S-130S; discussion 130S-131S.
-
1988: Grover G J; Schumacher W A; Simon M; Parham C
The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
Journal of cardiovascular pharmacology 1988;12(6):701-9.
-
1988: Grover G J; Fulmor I E
Thromboxane A2 antagonist and diltiazem-induced enhancement of contractile function: the effect of timing of treatment.
The Journal of pharmacology and experimental therapeutics 1988;247(2):445-52.
-
1988: Grover G J; Sleph P G; Parham C
The role of thromboxane A2 in reperfusion injury.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1988;188(4):504-8.
-
1988: Grover G J; Sleph P G; Parham C S
Effect of diltiazem on infarct size, reperfusion flow and flow reserve: the effect of timing of treatment.
The Journal of pharmacology and experimental therapeutics 1988;246(1):263-9.
-
1988: Grover G J; Schumacher W A
Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Journal of cardiovascular pharmacology 1988;11(1):29-35.
-
1987: Grover G J; Parham C S
The effect of diltiazem on ST-segment elevation and myocardial blood flow distribution during pacing-induced ischemia.
European journal of pharmacology 1987;143(1):109-17.
-
1987: Grover G J; Parham C S
Effect of intracoronary diltiazem on ST-segment elevation and myocardial blood flow during pacing-induced ischemia.
Journal of cardiovascular pharmacology 1987;10(5):548-54.
Sign-in to see more
